Your browser doesn't support javascript.
loading
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.
Peters, Solange; Shaw, Alice T; Besse, Benjamin; Felip, Enriqueta; Solomon, Benjamin J; Soo, Ross A; Bearz, Alessandra; Gadgeel, Shirish M; Lin, Chia-Chi; Kao, Steven; Seto, Takashi; Masters, Elizabeth T; Abbattista, Antonello; Clancy, Jill S; Thurm, Holger; Reisman, Arlene; Peltz, Gerson; Ross Camidge, D.
Afiliação
  • Peters S; Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland. Electronic address: Solange.Peters@chuv.ch.
  • Shaw AT; Massachusetts General Hospital, Boston, MA, USA. Electronic address: ashaw1@mgh.harvard.edu.
  • Besse B; Gustave Roussy Cancer Campus, Villejuif, France; Paris-Sud University, Orsay, France. Electronic address: Benjamin.BESSE@gustaveroussy.fr.
  • Felip E; Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain. Electronic address: efelip@vhio.net.
  • Solomon BJ; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Electronic address: Ben.Solomon@petermac.org.
  • Soo RA; National University Cancer Institute, Singapore. Electronic address: ross_soo@nuhs.edu.sg.
  • Bearz A; National Cancer Institute, Aviano, Italy. Electronic address: abearz@cro.it.
  • Gadgeel SM; University of Michigan/Rogel Cancer Center, Ann Arbor, MI, USA. Electronic address: sgadgeel@med.umich.edu.
  • Lin CC; National Taiwan University Hospital, Taipei, Taiwan. Electronic address: cclin1@ntu.edu.tw.
  • Kao S; Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia. Electronic address: Steven.Kao@lh.org.au.
  • Seto T; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan. Electronic address: setocruise@gmail.com.
  • Masters ET; Pfizer Oncology, New York, NY, USA. Electronic address: elizabeth.masters@pfizer.com.
  • Abbattista A; Pfizer Oncology, Milan, Italy. Electronic address: antonello.abbattista@pfizer.com.
  • Clancy JS; Pfizer Oncology, Cambridge, MA, USA. Electronic address: Jill.S.Clancy@pfizer.com.
  • Thurm H; Pfizer Oncology, La Jolla, CA, USA. Electronic address: holger.thurm@pfizer.com.
  • Reisman A; Pfizer Global Product Development, New York, NY, USA. Electronic address: Arlene.Reisman@pfizer.com.
  • Peltz G; Pfizer Oncology, Groton, CT, USA. Electronic address: Gerson.Peltz@pfizer.com.
  • Ross Camidge D; University of Colorado, Aurora, CO, USA. Electronic address: Ross.Camidge@ucdenver.edu.
Lung Cancer ; 144: 10-19, 2020 06.
Article em En | MEDLINE | ID: mdl-32344248
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Lung Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de publicação: Irlanda
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Lung Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de publicação: Irlanda